Posted by Michael Wonder on 05 Sep 2019
Tricida announces submission of new drug application for veverimer for the treatment of metabolic acidosis in patients with chronic kidney disease
4 September 2019 - New drug application submitted under the FDA’s accelerated approval program.
Tricida announced today that it has submitted a new drug application to the U.S. FDA under the accelerated approval program for approval of veverimer for the treatment of metabolic acidosis in patients with chronic kidney disease.
The submission is supported by data from Tricida’s successful Phase 3 clinical trials that were recently published in back-to-back publications in The Lancet (March 2019 and June 2019).
